Cover Image
Market Research Report

Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 785653
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
Published: January 28, 2019 Content info: 113 Pages
Description

About this market

Technological advances in diagnostics to drive market growth. The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix. Colposcopy is a more advanced technique like a Pap test, which allows the examiner to take abnormal cell tissues from the cervix. Technavio's analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.

Market Overview

Advent of vaccines

The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV. This is primarily due to the increasing research on developing highly advanced vaccines with a longer half-life. Vaccines were proved to have strong efficacy toward the prevention of various disease-causing viruses and highly effective toward the prevention of various indications caused by HPV.

Multiple-dose schedules of vaccines

Despite the availability of vaccines for the prevention of indications caused by HPV, the market faces a challenge from their recurring doses. As the vaccines that are currently approved for HPV are developed for administering through invasive methods such as subcutaneous route, the need for multiple doses affects the patient adherence toward the completion of the dose cycle.

For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including ALLERGAN and Bausch Health the competitive environment is quite intense. Factors such as the advent of vaccines and the technological advances in diagnostics, will provide considerable growth opportunities to human papillomavirus (HPV) manufactures. ALLERGAN, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR30751

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Topical - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Bausch Health
  • GlaxoSmithKline plc.
  • Lee's Pharmaceutical Holdings Limited
  • Merck Sharp & Dohme Corp.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: RoA - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by RoA
  • Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Topical - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Topical - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by RoA
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Decision framework
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: ALLERGAN - Vendor overview
  • Exhibit 46: ALLERGAN - Product segments
  • Exhibit 47: ALLERGAN - Organizational developments
  • Exhibit 48: ALLERGAN - Geographic focus
  • Exhibit 49: ALLERGAN - Segment focus
  • Exhibit 50: ALLERGAN - Key offerings
  • Exhibit 51: ALLERGAN - Key customers
  • Exhibit 52: Bausch Health - Vendor overview
  • Exhibit 53: Bausch Health - Product segments
  • Exhibit 54: Bausch Health - Organizational developments
  • Exhibit 55: Bausch Health - Geographic focus
  • Exhibit 56: Bausch Health - Segment focus
  • Exhibit 57: Bausch Health - Key offerings
  • Exhibit 58: Bausch Health - Key customers
  • Exhibit 59: GlaxoSmithKline plc. - Vendor overview
  • Exhibit 60: GlaxoSmithKline plc. - Business segments
  • Exhibit 61: GlaxoSmithKline plc. - Organizational developments
  • Exhibit 62: GlaxoSmithKline plc. - Geographic focus
  • Exhibit 63: GlaxoSmithKline plc. - Segment focus
  • Exhibit 64: GlaxoSmithKline plc. - Key offerings
  • Exhibit 65: GlaxoSmithKline plc. - Key customers
  • Exhibit 66: Lee's Pharmaceutical Holdings Limited - Vendor overview
  • Exhibit 67: Lee's Pharmaceutical Holdings Limited - Business segments
  • Exhibit 68: Lee's Pharmaceutical Holdings Limited - Organizational developments
  • Exhibit 69: Lee's Pharmaceutical Holdings Limited - Segment focus
  • Exhibit 70: Lee's Pharmaceutical Holdings Limited - Key offerings
  • Exhibit 71: Lee's Pharmaceutical Holdings Limited - Key customers
  • Exhibit 72: Merck Sharp & Dohme Corp. - Vendor overview
  • Exhibit 73: Merck Sharp & Dohme Corp. - Business segments
  • Exhibit 74: Merck Sharp & Dohme Corp. - Organizational developments
  • Exhibit 75: Merck Sharp & Dohme Corp. - Geographic focus
  • Exhibit 76: Merck Sharp & Dohme Corp. - Segment focus
  • Exhibit 77: Merck Sharp & Dohme Corp. - Key offerings
  • Exhibit 78: Merck Sharp & Dohme Corp. - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: List of abbreviations
Back to Top